In his words, the Orbans had already retired


“There is a correlation between the number of antibodies after vaccination and the T-cell immune response,” says biologist László Puskás, based on more than half a hundred tests.

“Based on the experience so far, it is probable that those who did not develop antibody protection as a result of the vaccination will not develop a high percentage of cellular immunity,” said László Puskás, biologist at Népszava, managing director of Avidin Kft. few studies have been conducted so far to draw a final conclusion. What makes the issue particularly acute is that in several countries, some elderly patients vaccinated with Sinopharm Covid vaccine in China found that tests did not detect antibodies against the virus. This was also experienced by many Hungarian vaccinees. At the same time, according to Chief National Officer Cecília Müller, there is no cause for concern, because another mechanism of the body’s defense, cellular immunity, may have developed from this. However, this is not easy to measure. Laboratory tests demonstrating such cellular immunity will not be performed on applicants by the epidemiological authorities. Anyone who wants this is the only way to look for a market provider. Avidin Kft. From Szeged, which entered the market with such a test a week ago, developed a test that can detect from the blood whether the so-called T-cell protection has developed. As we learned from the executive, 60-70 investigations have been conducted so far.

– From these few samples, it could be seen that we found cell protection much less often in those for whom we could not measure antibody. That is, there is a correlation between the number of antibodies after vaccination and the T-cell immune response – said László Puskás. The biologist noted that they have no information on what vaccine their vaccine blood people have been vaccinated with. Their method is a special method in which cellular elements are isolated from the blood, a mixture of proteins that mimics a viral infection is added to it, and then they look for the appearance of so-called coronavirus-specific memory T cells. Anyone who has been infected or encountered the virus in any other way, such as by vaccination, or a piece of the virus, will remember this. And if the body is later re-infected, the memory cells are activated. “They have a helper and a cytotoxic” team. ” When cytotoxics are revived, they kill the cells in which the virus has multiplied. Helping cells, in turn, support their function. If someone had an antibody response but disappeared over time, that doesn’t mean they don’t have protection either. When memory immune cells are reactivated, the antibody response also appears through it, the expert told our paper. Not only have the epidemiological authorities in other countries come to the principle that if the two Sinopharm vaccinations are not enough, a third should be given. But this is also recommended by the vaccine manufacturer, in the package leaflet. Others say that if the two doses of Sinopharm did not work well enough, one or two doses of another type of vaccine should be given for the third time. In this respect, however, the Hungarian authorities do not want to make a decision, they only give evasive answers. In contrast, in the United Arab Emirates and Bahrain, for example, those vaccinated with Sinopharm vaccine also receive a third dose because of their age or health, but not Chinese serum but Pfizer. In Hungary, a possible third dose has not been discussed yet, although there are growing suspicions that the Chinese vaccine does not provide adequate protection. Stakeholders have already created a Facebook group. In four or five days, the number of members increased to about 3-4 thousand. A petition has recently been launched calling on decision-makers to demand a free test and, if necessary, a third vaccination. After their antibody tests a few weeks after vaccination showed little or no antibody production close to the limit, they fear that they have not developed adequate protection. To know that no substantive response was received until the publication of our article. Miklós Kásler, Minister of Human Resources, announced in May that a comprehensive study will be launched to determine the effectiveness of vaccines. But when the results of this were searched to reassure those concerned, he averted the investigation for one year.

Coronavirus vaccination from a pharmacy

The vaccine will be marketed by Moderna in Central and Eastern Europe and Israel, the manufacturer said in a statement. The vaccines will be distributed by a company called Medison Pharma and will go on sale in 20 countries. In addition to Hungary, Moderna will be available in Poland, the Czech Republic, Romania, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia and Herzegovina, Kosovo, Northern Macedonia, Montenegro and Israel. The communication did not specify exactly when the vaccine could start to be distributed in the countries listed above. Our magazine asked the Hungarian Medicines Authority if and when this vaccine will be marketed in pharmacies, but we did not receive a response until the publication of our article. D. A.

You can gain time with it

“Better than nothing,” said Catherine Bennett, an epidemiologist at Deakin University in Australia, praising the Chinese Sinopharm coronavirus vaccine. The epidemiologist explained to the online news magazine The Diplomat that although this vaccine is less effective than other sera, it still has a place in the fight against the pandemic, it could save time “while other vaccines may become more widespread.” Bennett’s view seems to support Bahrain and the UAE were among the first to vote in favor of China’s Sinopharm, the two Middle Eastern states have long been among the world’s leading vaccines, but doubts have been raised about the vaccine’s effectiveness in the meantime. In the Emirates, those who did not show an adequate immune response after two doses received a third dose in March, and in May both countries announced that everyone would receive a third, “booster” dose after six months. also offered those concerned that the You can also choose the Pfizer vaccine instead of Sinopharm. In Bahrain, the latter is specifically recommended for vulnerable groups – including those over 50, the obese and the chronically ill. According to the Wall Street Journal, they went even further in Dubai: they started vaccinating those who originally received the Chinese vaccine with two doses of Pfizer in pretty quiet silence.

All this shows that Sinopharm was suitable for Bahrain and the Emirates at the time of the severe vaccine shortage at the beginning of the year, but the drug was only a bridging solution, no longer intended to protect the population in the long run. In the Middle Eastern country, a similar principle seems to be applied to that outlined by Dr. Theo Vos, a researcher at the University of Washington, in a recent interview with our paper. “When resources are scarce, a Sinopharm or AstraZeneca vaccine is much better than getting sick. But if a country has enough vaccinations, it is clear that a higher-potency serum is worth using, ”the expert said. Regardless of the concerns raised, however, the WHO also nodded to the emergency use of Sinopharm, and the authorities in 73 countries also gave the serum a green light. According to some experts, this is mainly due to the global vaccine shortage, exacerbated by India, which promises to be one of the largest exporters, halting exports in April due to the deteriorating domestic epidemic. Based on the “better than nothing” principle, Sinopharm could be a bridging solution until a pandemic rages around the world and there are not enough of the vaccines that are proving more effective. The Chinese manufacturer promises to produce 3 billion doses this year, and by preliminary agreements, production of the vaccine is also expected to begin in Argentina, Bangladesh, the Emirates and Serbia. There is expected to be a demand for these stocks in the developing world, but in the long run it is by no means certain to have a place in the global vaccine supply, especially as more effective alternatives become more widely available. Both Pfizer and Moderna have promised to produce 3-3 billion from its vaccine in 2022, which studies show is superior to the Chinese vaccine in every way. It is not inconceivable, then, that other countries will follow the example of Bahrain and the Emirates in the future – and guarantee the protection of those originally vaccinated with Sinopharm with Pfizer or another more effective vaccine. – ANDRÁS ROSTOVÁNYI

It was tested on young people

Considering only clinical trials, Sinopharm lags behind Pfizer, Moderna, or Sputnik V, which is more than 90 percent effective, but does not perform as poorly: the vaccine provides 78 percent protection against against infection. However, the predominance of the results may have been due to the predominance of young healthy men in the studies; the mean age was 36 years, and only 16 percent of participants were female. The World Health Organization (WHO) has therefore not been able to determine whether the vaccine provides adequate protection in the over-60 age group. The Wall Street Journal reported a survey in Serbia that specifically showed that the vaccine was less successful in the elderly: 29 percent of participants over the average age of 65 did not find an adequate antibody response three months after the second dose, in addition to the study. Ten out of 150 people became ill. – R. A.


Source: Népszava by nepszava.hu.

*The article has been translated based on the content of Népszava by nepszava.hu. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!